| Prof. Julien Haroche, MD, PhD | Welcome | Welcome |
| Omar Abdel-Wahab, MD, PhD and Benjamin Durham, MD; | Insights into the Cell-of-Origin of the Histiocytoses Using Patient-‐Derived Xenograft Murine Models | Insights into the Cell-of-Origin of the Histiocytoses Using Patient-‐Derived Xenograft Murine Models |
| Lorenzo Dagna, MD, PhD | CCL18 in Erdheim-Chester Disease: Potential Implications in the Pathogenesis | Not available |
| Matthew Collin, MD | The Hematopoietic Origin of Adult Histiocytosis | Not available |
| Matthias Papo, MD | Erdheim-Chester disease is frequently associated with myeloproliferative neoplasms and myelodysplastic syndromes: a systematic clinical and molecular series of 189 patients | Not available |
| Fleur Cohen-Aubart, MD & Wilfred Le Goff, MD | Marked alteration of circulating immune cells in Erdheim-Chester disease in a large single-center series of 46 patients | Not available |
| Roei D. Mazor, MD | Biopsy Specimens of Erdheim-Chester Disease Patients | Not available |
| Filip Janku, MD, PhD | Clinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester Disease | Clinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester Disease |
| Tahla Munir, MD | A Single- centre Experience of Treating Adult Patients with Langerhans' cell
Histiocytosis and Erdheim Chester Disease; Sustained Response to Oral Methotrexate in Frontline and Relapsed Disease | A Single- centre Experience of Treating Adult Patients with Langerhans' cellHistiocytosis and Erdheim Chester Disease; Sustained Response to Oral Methotrexate in Frontline and Relapsed Disease |
| Achille Aouba, MD, PhD | Superior Efficacy and Equivalent Safety of Double-dose Anakinra in Erdheim-Chester Disease | Superior Efficacy and Equivalent Safety of Double-dose Anakinra in Erdheim-Chester Disease |
| Tahla Munir, MD | Single Centre Experience of Treating Four Cases of Relapsed/Refractory BRAF Mutated Erdheim Chester Disease (ECD) / Langerhan’s Cell Histiocytosis(LCH) with Oral BRAF Inhibitor Vemurafenib | Single Centre Experience of Treating Four Cases of Relapsed/Refractory BRAF Mutated Erdheim Chester Disease (ECD) / Langerhan’s Cell Histiocytosis(LCH) with Oral BRAF Inhibitor Vemurafenib |
| Fleur Cohen-Aubart, MD and Julien Haroche, MD, PhD | The LOVE trial: preliminary results | Not available |
| Juvianee Estrada-Veras, MD | Dabrafenib and Trametinib as Potential Therapy in BRAF V600E Positive ErdheimChester Disease (ECD): Preliminary Results | Not available |
| Eli L. Diamond, MD | Phase 2 Trial of Single-Agent Cobimetinib for Adults with Histiocytic Disorders: Preliminary Results | Not available |
| Tahla Munir, MD | Dabrafenib in combination with Trametinib is effective in treatment of refractory BRAF mutated mixed histiocytic disease- A Case report | Dabrafenib in combination with Trametinib is effective in treatment of refractory BRAF mutated mixed histiocytic disease- A Case report |
| Diana Melo, MD | Spectrum of Cardiovascular Involvement in Erdheim-Chester Disease Evaluated by Multimodality Imaging | Not available |
| Mark Heaney, MD, Julien Haroche, MD, PhD, Eli L. Diamond, MD, Matthew Collin, MD, Lorenzo Dagna, MD, PhD | Panel Discussion: ECD Patient Registry: Community Tool for Research | Panel Discussion: ECD Patient Registry: Community Tool for Research |
| Augusto Vaglio, MD, PhD, Juvianee Estrada-Veras, MD, Filip Janku, MD, PhD, Omar Abdel-Wahab, MD, PhD, Javier Martin, MD, PhD | Panel Discussion: Proposed ECD GWAS Study | Panel Discussion: Proposed ECD GWAS Study |
| Corrado Campochiaro, MD | Management of ECD Symptoms and Side Effects of Treatments | Management of ECD Symptoms and Side Effects of Treatments |
| Giulio Cavalli, MD | Adult Onset (Infratentorial) Leukoencephalopathy as Presenting Manifestation of Erdheim-Chester Disease | Adult Onset (Infratentorial) Leukoencephalopathy as Presenting Manifestation of Erdheim-Chester Disease |
| Carine Courtillot, MD | Endocrine manifestations in Erdheim-Chester disease | Endocrine manifestations in Erdheim-Chester disease |
| Benjamin Durham, MD | Insights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Murine Models | Insights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Murine Models |
| Marina Ferrarini, MD | Tailoring Treatment for Erdheim-Chester Disease: Focus on ECD | Tailoring Treatment for Erdheim-Chester Disease: Focus on ECD |
| Ronald Go, MD | Efficacy of Cladribine (2-CdA) in the Treatment of Erdheim-Chester Disease (ECD) | Efficacy of Cladribine (2-CdA) in the Treatment of Erdheim-Chester Disease (ECD) |
| Filip Janku, MD, PhD | Encouraging activity of MEK inhibitor trametinib in patients with Erdheim-Chester disease irrespective of BRAF mutation statusClinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester Disease | Encouraging activity of MEK inhibitor trametinib in patients with Erdheim-Chester disease irrespective of BRAF mutation statusClinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester Disease |
| Javier Martin, MD, PhD | Future Genetic Studies in Erdheim-Chester disease – GWAS Study | Future Genetic Studies in Erdheim-Chester disease – GWAS Study |
| Kenneth McClain, MD, PhD | Elevated CSF Osteopontin and Circulating Cells with BRAF Mutations in Patients with Langerhans Cell Histiocytosis-Associated Neurodegeneration -A Model for ECD? | Elevated CSF Osteopontin and Circulating Cells with BRAF Mutations in Patients with Langerhans Cell Histiocytosis-Associated Neurodegeneration -A Model for ECD? |
| Augusto Vaglio, MD, PhD | MRI evidence of cardiac involvement in Erdheim-Chester disease | MRI evidence of cardiac involvement in Erdheim-Chester disease |
| Julien Haroche, MD, PhD & Kathleen Brewer | Closing | Not available |
